Inventor · disambiguated record
Peter Sennhenn
Also filed as: SENNHENN PETER · SENNHENN PETER C · SENNHENN PETER CHRISTIAN
13 granted patents·13 pending applications·9 citations·filing 2006–2025
85Inventor score
Files withIOMX THERAPEUTICS AG10VANDRIA SA5AUGUSTINE THERAPEUTICS2EISBACH BIO GMBH2HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH2
Top patents by PatentIndex Score
26 records- 0193US11820751B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2022·Granted Nov 21, 2023·3 cites·6 claims
- 0284US12473269B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Nov 18, 2025·0 cites·12 claims
- 0383US12358884B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 0482US12351567B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 8, 2025·0 cites·19 claims
- 0573US10647687B2Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-deathHELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH·Filed 2015·Granted May 12, 2020·2 cites·22 claims
- 0673US9802956B2Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-deathHELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)·Filed 2014·Granted Oct 31, 2017·3 cites·12 claims
- 0771US2025084076A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0871US2025101015A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0964US2025340886A1Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 1063US10280179B2Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-deathHelmholtz Zentrum Munchen—Deutches Forschungszentrum Fur Gesundheit und Umwelt·Filed 2017·Granted May 7, 2019·1 cites·17 claims
- 1162US12139480B25-thiazolecarboxamide kinase inhibitor and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Nov 12, 2024·0 cites·18 claims
- 1262USRE48992ESpiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-deathHELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH·Filed 2014·Granted Mar 29, 2022·0 cites·30 claims
- 1362US2024051933A1Urolithin derivatives and therapeutic usesVANDRIA SA·Filed 2023·Application pending·0 cites
- 1457US2021379067A1Dasatinib and another 5-thiazolecarboxamide kinase inhibitor, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 1556US2025275973A1Use of alc1 inhibitors and synergy with parpiEISBACH BIO GMBH·Filed 2023·Application pending·0 cites
- 1654US2025051319A1Compounds and use thereof as hdac6 inhibitorsAUGUSTINE THERAPEUTICS·Filed 2022·Application pending·0 cites
- 1752US12421222B2Substituted quinazolines as HDAC6 inhibitorsAUGUSTINE THERAPEUTICS·Filed 2025·Granted Sep 23, 2025·0 cites·29 claims
- 1851US12172993B2Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Dec 24, 2024·0 cites·53 claims
- 1950US2024033363A1ALC1 Inhibitors and Synergy with PARPiEISBACH BIO GMBH·Filed 2021·Application pending·0 cites
- 2048US12338440B2Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2018·Granted Jun 24, 2025·0 cites·33 claims
- 2147US2023192701A1Bicyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 2244US8203001B2Chemical compoundsREISER ULRICH·Filed 2007·Granted Jun 19, 2012·0 cites·9 claims
- 2344US2009186901A1Chemical compoundsREISER ULRICH·Filed 2007·Application pending·0 cites
- 2444US2023348453A1Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 2542US2007004684A1Alpha-Carbolines as CDK-1 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2006·Application pending·0 cites
- 2641US2023228760A1Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →